Cibinetide
Based on 6 publication(s) in Google Scholar
Cibinetide (ARA290) is a non-hematopoietic Erythropoietin analog. Cibinetide selectively activates the EPOR/CD131 heteromer IRR without activating EPOR homodimers, and exerts neuroprotective effects through β-common receptor signaling. Cibinetide inhibits Cathepsin K/OSCAR/OC-STAMP/DC-STAMP/NFATC1, increases OPG and Alkaline phosphatase, and decreases CD115. Cibinetide modulates SIRT1/NF-κB/IL-1β signaling, reduces inflammatory infiltration and periapical bone loss, protects pancreatic islets, reduces IBMIR-related platelet consumption, and prolongs graft function. Cibinetide extends healthspan and attenuates age-related cardiac and body weight decline. Cibinetide can be used in research on cerebral ischemic stroke, sarcoidosis-associated small fiber neuropathy, and type 1 diabetes.
For research use only. We do not sell to patients.
- Purity : 99.96%
- CAS No.: 1208243-50-8
- Formula: C51H84N16O21
- Molecular Weight:1257.31
-
Storage:
Sealed storage, away from moisture.
Powder -80°C, 2 years , -20°C, 1 year* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Protocols
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Cibinetide
More
Customer Validation & Images
-
IHC
All Cathepsin Isoforms
More
Biological Activity
Description
|
cathepsin K |
SIRT1 |
IL-1β |
In Vitro
Cibinetide (3-300 µM; 48 hours) does not reduce BMDM viability[1].
Cibinetide (150 µM; added on days 0-3; stained on day 4) exhibits the strongest inhibitory effect on osteoclastogenesis when added on day 0 of RANKL-induced BMDM differentiation[1].
Cibinetide (150 µM) inhibits the expression of CTSK, OSCAR, DC-STAMP, OC-STAMP, and NFATC1 in RANKL/M-CSF-stimulated BMDMs[1].
Cibinetide (150 µM; 10 U/mL EPO; LPS on day 2; TRAP staining on day 4) antagonizes LPS- and EPO-enhanced osteoclastogenesis in BMDM cultures[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Cibinetide (300 µg/kg/day; 5 consecutive days; combined with EPO on day 1 and day 4) attenuates EPO-driven expansion of osteoclast progenitor cells and reduces CD115 surface expression on osteoclast precursors in healthy female mice[1].
Cibinetide (30-100 µg/kg; i.p.; once or twice daily; administered at the onset of reperfusion) attenuates cerebral infarction in mice after MCAO at 30 µg/kg twice daily, whereas 30 or 100 µg/kg once daily has no such effect[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6J (C57BL/6J-RccHsd; female; 12 weeks old)[1]
-
Dosage:120 µg/kg
-
Administration:3 times per week; for 4 weeks
-
Result:Hemoglobin levels were unchanged.
Cortical tissue mineral density increased by 5.8%.
Trabecular tissue mineral density increased by 5.2%.
BV/TV was unchanged.
Whole-bone OPG mRNA increased by 52.4%.
RANKL mRNA was unchanged.
The percentages of CD11b−ALP+ preosteoblasts and CD11b−CD115+ preosteoclasts in bone marrow were unchanged.
Surface ALP expression on CD11b− bone marrow cells increased by 25.59%.
Surface CD115 expression decreased by 17.79%.
-
Animal Model:C57BL/6J (C57BL/6J-RccHsd; female; 13 weeks old)[1]
-
Dosage:300 µg/kg/day (alone or with EPO 120 U on days 1 and 4)
-
Administration:daily; for 5 consecutive days; EPO on days 1 and 4
-
Result:EPO alone increased Lin−CD11b−Ly6ChiCD115+ osteoclast progenitors by 81.06%.
Concurrently reduced this population by 42.8% compared with EPO alone.
Osteoblast precursor numbers were unchanged.
Downregulated CD115 surface expression on osteoclast precursors both alone and in combination with EPO; EPO alone had no effect.
Short-term µCT showed no changes in bone parameters in any group.
-
Animal Model:C57BL/6J (male, adult, 22-25 g)[3]
-
Dosage:30 µg/kg (once daily); 30 µg/kg (twice daily); 100 µg/kg (once daily)
-
Administration:i.p.; once daily or twice daily; started at beginning of reperfusion
-
Result:Brain infarction volume was lower in the 30 µg/kg twice-daily group than in the MCAO group.
The 30 µg/kg once-daily and 100 µg/kg once-daily groups did not show this reduction.
Chemical Information
-
CAS No. 1208243-50-8
-
Appearance Solid
-
Molecular Weight 1257.31
-
Formula C51H84N16O21
-
Color White to off-white
-
Synonyms
ARA290
-
Sequence
{Glp}-Glu-Gln-Leu-Glu-Arg-Ala-Leu-Asn-Ser-Ser
-
Sequence Shortening
{Glp}-EQLERALNSS
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Sealed storage, away from moisture
Powder -80°C 2 years -20°C 1 year * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (6)
-
Journal Impact Factor
-
Most Recent
-
CNS Neurosci Ther
Erythropoietin-derived peptide ARA290 mediates brain tissue protection through the β-common receptor in mice with cerebral ischemic stroke. [Abstract]2024 Mar;30(3):e14676. PMID: 38488446 -
Int J Mol Sci
2024 Mar 29;25(7):3854. PMID: 38612664 -
Immunology
EPOR activation attenuates colitis via enhancing LC3B-dependent apoptotic cell clearance. [Abstract]2025 Sep;176(1):33-48. PMID: 37204242 -
Toxicol In Vitro
An engineered non-erythropoietic erythropoietin-derived peptide, ARA290, attenuates doxorubicin induced genotoxicity and oxidative stress. [Abstract]2020 Aug:66:104864. PMID: 32335150
Cibinetide purchased from MedChemExpress. Usage Cited in: Toxicol In Vitro. 2020 Aug:66:104864. [Abstract]
Representative photomicrographs demonstrate the results of the TUNEL assay. Alterations in apoptotic cells are assessed using the ratio of green fluorescence. (For interpretation of the references to colour in this figure legend, the reader is referred to the web version of this article.)
-
-
Solvent & Solubility
In Vitro:
H2O : 66.67 mg/mL (53.03 mM; adjust pH to 8 with NH3·H2O)
0.1 M NaOH : ≥ 50 mg/mL (39.77 mM)
DMSO : ≥ 34 mg/mL (27.04 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 2.5 mg/mL (1.99 mM); Clear solution; Need ultrasonic and warming and heat to 37°C
Purity & Documentation
-
Data Sheet (285 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Handling Instructions (2659 KB)
References
[1]. Awida Z, et al. The Non-Erythropoietic EPO Analogue Cibinetide Inhibits Osteoclastogenesis In Vitro and Increases Bone Mineral Density in Mice. International journal of molecular sciences. 2021 Dec 21;23(1):55. [Content Brief]
[3]. Wang RL, et al. Erythropoietin-derived peptide ARA290 mediates brain tissue protection through the β-common receptor in mice with cerebral ischemic stroke. CNS neuroscience & therapeutics. 2024 Mar;30(3):e14676. [Content Brief]
[5]. Gemignani F, et al. Non-length-dependent small fiber neuropathy: Not a matter of stockings and gloves. Muscle & nerve. 2022 Jan;65(1):10-28. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO / 0.1 M NaOH / H2O | 1 mM | 0.7953 mL | 3.9767 mL | 7.9535 mL | 19.8837 mL |
| 5 mM | 0.1591 mL | 0.7953 mL | 1.5907 mL | 3.9767 mL | |
| 10 mM | 0.0795 mL | 0.3977 mL | 0.7953 mL | 1.9884 mL | |
| 15 mM | 0.0530 mL | 0.2651 mL | 0.5302 mL | 1.3256 mL | |
| 20 mM | 0.0398 mL | 0.1988 mL | 0.3977 mL | 0.9942 mL | |
| 25 mM | 0.0318 mL | 0.1591 mL | 0.3181 mL | 0.7953 mL | |
| 0.1 M NaOH / H2O | 30 mM | 0.0265 mL | 0.1326 mL | 0.2651 mL | 0.6628 mL |
| H2O | 40 mM | 0.0199 mL | 0.0994 mL | 0.1988 mL | 0.4971 mL |
| 50 mM | 0.0159 mL | 0.0795 mL | 0.1591 mL | 0.3977 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Cibinetide Related Classifications
HY-P0168 Related Classifications
Powered by Bioz
Keywords
- Cibinetide
- 1208243-50-8
- ARA290
- ARA 290
- ARA-290
- Erythropoietin Receptor (EpoR)
- Cathepsin
- Nuclear Factor of activated T Cells (NFAT)
- Phosphatase
- Sirtuin
- NF-κB
- Interleukin Related
- c-Fms
- EPOR/CD131
- IBMIR
- SIRT1/NF-κB/IL-1β
- allograft rejection
- erythropoietin analogue
- innate repair receptor
- neuroprotection
- osteoclast differentiation
- β-common receptor
- βCR
- Inhibitor
- inhibitor
- inhibit